GlassScriptPhysician profile
Kelley L Young
NPI 1982731717
$938.00
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $185.57 | 2019-2020 | |
| Lilly USA, LLC | $56.19 | 2019 | |
| Tersera Therapeutics LLC | $52.24 | 2019 | |
| Seagen INC. | $51.41 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $44.86 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.66 | 2019 | |
| Tesaro, INC. | $37.06 | 2019 | |
| Abbvie INC. | $35.11 | 2019-2020 | |
| Genzyme Corporation | $28.41 | 2019 | |
| Gilead Sciences, INC. | $27.80 | 2019 | |
| Amgen INC. | $25.03 | 2019 | |
| Puma Biotechnology, INC. | $24.33 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $17.91 | 2019 | |
| Janssen Biotech, INC. | $14.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.42 | 2019 | |
| Cranial Technologies, INC | $11.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.